USFDA concludes audit at Jubilant Pharmova’s step down subsidiary’s solid dosage formulations facility

03 Feb 2024 Evaluate

United States Food and Drug Administration (USFDA) has concluded audit at Jubilant Pharmova’s wholly-owned subsidiary -- Jubilant Pharma’s subsidiary -- Jubilant Generics’ solid dosage formulations facility on February 2, 2024 at Roorkee site, India. The USFDA has issued 4 observations pursuant to the completion of audit. The company will submit an action plan on the observations.

The company currently supplies only one product to US from Roorkee facility, that contributed less than one percent of Jubilant Pharmova’s 9M’FY24 revenues.

Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.

Jubilant Pharmova Share Price

1073.50 4.30 (0.40%)
05-Dec-2025 15:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.00
Dr. Reddys Lab 1276.55
Cipla 1520.55
Zydus Lifesciences 933.10
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×